Sevirumab. Protovir, MSL 109, EV2 7, SDZ MSL 109.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003587:Cytomegalovirus / Q000187:drug effects; D003586:Cytomegalovirus Infections / Q000517:prevention & control; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy* / Q000821:virology; D015507:Drugs, Investigational / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008826:Microbial Sensitivity Tests; D011817:Rabbits
D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D015507:Drugs, Investigational; C409204:sevirumab